C-RAD announced today that the previously announced sales and distribution agreement with Elekta has been expanded to include China. The agreement enables Elekta to offer C-RAD's surface image guided radiation therapy (SIGRT) technology for stereotactic radiosurgery (SRS), stereotactic body radiotherapy (SBRT) and motion management.
C-RAD and Elekta engaged in a strategic cooperation to provide a comprehensive solution based on C-RAD's SIGRT solution and Elekta linacs for the North American market in July 2019. The objective is to meet the growing demand of SIGRT in advanced radiation therapy. This agreement has now been amended to include the Chinese market and allows Elekta to offer C-RAD's products to the installed base and to new customers.
"The Chinese market is one of the fastest growing radiation therapy markets worldwide with a huge potential for C-RAD." Says Tim Thurn, CEO of C-RAD "Together with our partners in China we have established C-RAD as the market leader. Most of the national cancer centers and many customers have adapted our technology to their daily workflow already."
Kurt Wang, President C-RAD China, says "I am excited that we will work together with Elekta to promote our SIGRT solution in China. Customers are challenged by high patient volume and the demand for precise radiation therapy. The C-RAD technology contributes equally to improve efficiency and precision. We see the same trend as in Europe and America, that SIGRT is on its way to become standard of care in China."
The Catalyst HD™ system, which integrates with Elekta linacs, provides gross patient positioning and postural positioning along with respiratory motion management. It extends the value of Elekta's high definition dynamic radiosurgery (HDRS) solution through complementary capabilities and technologies.
Anming Gong, Executive Vice President, Region China at Elekta, said: "The cooperation with C-RAD supports Elekta's focus on precision radiation medicine for its linac market segment in China. I believe SIGRT can help Chinese cancer clinics to approach precise radiation therapy in a very efficient way."
C-RAD's current cooperation with the distributor HGPT Beijing HGPT Technology & Trade Co. Ltd will continue, remaining an important part of C-RAD's efforts to be successful in China, addressing market opportunities outside the scope of the Elekta agreement.
C-RAD develops surface-guided imaging solutions for radiation therapy to allow highly accurate dose delivery to the tumor, and at the same time, to protect healthy tissue from unwanted exposure. Using high-speed 3D cameras combined with augmented reality, C-RAD supports the initial patient setup process and monitors the patient's motion during treatment to ensure high confidence, an efficient workflow, and improved accuracy. C-RAD monitors the patient's motion without the use of tattoos or additional imaging dose, to deliver the highest level of patient safety and comfort.
C-RAD. Inspiring excellence in cancer treatment.
C-RAD AB is listed on NASDAQ Stockholm.
For more information on C-RAD, please visit http://www.c-rad.com
For further information:
Tim Thurn, CEO C-RAD AB, Phone +46-18-666930, Email email@example.com
(c) 2020 Cision. All rights reserved., source Press Releases - English